SCHEMBL5367625

SCHEMBL5367625

Cc1c(Br)ccc2c1C(=Cc1ccc(N(C)C)cc1)C(=O)N2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 2/20 0.56
MAPT P10636 10/20 0.55
APP P05067 7/20 0.55
SNCA P37840 6/20 0.55
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
ALDH1A1 P00352 4/20 0.55
PDGFRB P09619 3/20 0.55
TDP1 Q9NUW8 3/20 0.55
MAPK1 P28482 2/20 0.55
LMNA P02545 2/20 0.55
RAB9A P51151 2/20 0.55
HPGD P15428 2/20 0.55
NPC1 O15118 1/20 0.55
GMNN O75496 1/20 0.55
MTOR P42345 1/20 0.55
BLM P54132 1/20 0.55
PMP22 Q01453 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7134014 0.87 RET (0.48) MAPTAPPSNCAMEN1KMT2A
SCHEMBL5359351 0.86 RET (0.57) MAPTAPPSNCAMEN1KMT2A
SCHEMBL7134022 0.84 LRRK2 (0.48) RET
SCHEMBL5377025 0.84 RET (0.54) MAPTAPPSNCAMEN1KMT2A
SCHEMBL7137405 0.82 IGF1R (0.45) MAPTMEN1KMT2APDGFRBRAB9A
SCHEMBL7136100 0.82 RET (0.67) MAPTAPPSNCAMEN1KMT2A
SCHEMBL7134871 0.82 RET (0.44) MAPTAPPSNCAMEN1KMT2A
SCHEMBL7132867 0.82 PDGFRB (0.55) MEN1KMT2APDGFRBCTRCPIM1
SCHEMBL5358699 0.82 GSK3B (0.45) MAPTAPPSNCAMEN1KMT2A
SCHEMBL7139052 0.81 METAP1 (0.55) METAP1MAPTAPPSNCAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK METAP1 3119/4885MAPT 3048/4885APP 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.